Summary
Due to their capacity to fight apoptosis, inflammation, and oxidative stress, naringin and its aglycone naringenin are considered valuable therapeutic agents for diabetes mellitus (DM). By examining clinical, in vitro, and in vivo studies found from inception until July 2024 on major electronic databases, we explored the pharmacological activities of naringin and naringenin in treating DM and associated risks. Naringin and naringenin improved insulin sensitivity, glucose metabolism, and insulin resistance by activating glucose transporter (GLUT)-4, and peroxisome proliferator-activated receptor (PPAR)-γ. They also possessed antioxidant and anti-inflammatory impacts through regulating mitogen-activated protein kinases (MAPK), nuclear factor kappa B (NF-κB), and Nrf2 signaling pathways. The
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.